Recent Company News

• 09:00 AM ET Nov 04, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:54 AM ET Dec 05, 2025
  

  Autos, healthcare, financial services best performers; energy, insurance and real estate lag:

• 04:46 AM ET Dec 05, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:54 AM ET Dec 05, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:12 AM ET Dec 05, 2025
  

  UCB upgrades FY25 financial guidance amidst robust year to date performance (€239.90, 0.00)

• 01:07 AM ET Dec 04, 2025
  

  UCB will present 21 abstracts at the American Epilepsy Society (AES) Annual Meeting 5-9 Dec (€239.80, 0.00)

• 03:58 PM ET Nov 25, 2025
  

  FDA grants orphan drug designation to zampilimab for IPF (€236.10, 0.00)

• 05:30 PM ET Nov 03, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:51 PM ET Nov 03, 2025
  

  Follow-up: U.S. FDA approves KYGEVVI as treatment for TK2d in adults and pediatric patients; availability and RPDPRV voucher status (€220.00, 0.00)